Featured Articles
Ophthotech Corporation (NASDAQ:OPHT) announce agreements with two US universities to progress gene therapy for autosomal dominant retinitis pigmentosa (adRP)
Ophthotech Corporation (NASDAQ: OPHT), a US-based biopharmaceutical company focused on the development of retinal disease therapies, has announced the execution of agreements with both the universities of Florida and Pennsylvania. The company, with a market capitalization of over $110M, aims to access university technology to build novel gene therapies for the treatment of adRP. The […]
Read full storyClinical genetics research into the variability of response to anti-VEGF treatment suggests common gene variants may have a limited contribution
Research led by a team at the Radboud University Medical Center in Nijmegen, the Netherlands, have shown that the response to anti-VEGF medication may arise from a complexity of interactions, rather than a small defined number of common genetic variants. The clinical genetics research involved a genome-wide association study (GWAS) of 678 nAMD patients revealing […]
Read full storyDiabetic retinopathy screening study shows that financial incentives may have a negative effect on attendance at clinical appointments
Research conducted at Imperial College London has found that financial incentives designed to encourage patients to attend diabetic eye screening result in fewer attendees, compared to no incentive at all. The randomised study demonstrated that participants receiving any incentive were actually less likely to attend for appointment compared to participants receiving no incentive. The researchers […]
Read full story